Sign In
Buy VTVT
$32.35
-0.330 (-1.01%)
At Close: Jul 31, 2026
CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMIT
08:30am, Tuesday, 19'th Mar 2024
Podium presentation will include clinical updates from the Company's Phase 2 clinical trials investigating azeliragon, in combination with radiation therapy with or without temozolomide, in newly diag
vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
08:00am, Wednesday, 13'th Mar 2024
HIGH POINT, N.C., March 13, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an oral adjunctive therapy to insuli
The Top 3 Healthcare Stocks to Buy on Weakness in 2024
03:49pm, Monday, 04'th Mar 2024
Healthcare stocks have started the year off very strongly, propelled by excitement about weight loss drugs and investments by Nvidia (NASDAQ: NVDA ). The sector is also getting a lift from the U.S. Fe
vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes
08:00am, Monday, 04'th Mar 2024
HIGH POINT, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunct
vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare Conference
08:00am, Friday, 01'st Mar 2024
HIGH POINT, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunct
vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D Fund
08:00am, Wednesday, 28'th Feb 2024
Proceeds to fully fund first Phase 3 study of cadisegliatin, expected to initiate in mid-2024 Proceeds to fully fund first Phase 3 study of cadisegliatin, expected to initiate in mid-2024
CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCE
04:00pm, Thursday, 22'nd Feb 2024
WESTON, Fla. , Feb. 22, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening
vTv Therapeutics Announces 2023 Third Quarter Financial Results and Provides Corporate Update
04:30pm, Thursday, 09'th Nov 2023
HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjuncti
vTv Therapeutics to Participate at the Stifel 2023 Healthcare Conference
08:00am, Wednesday, 08'th Nov 2023
HIGH POINT, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjuncti
vTv Therapeutics Appoints Thomas Strack, M.D., as Chief Medical Officer
08:00am, Thursday, 02'nd Nov 2023
HIGH POINT, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjuncti
vTv Therapeutics Announces Sale of Shares in Reneo Pharmaceuticals for Proceeds of $4.4 Million
08:00am, Wednesday, 01'st Nov 2023
HIGH POINT, N.C., Nov. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjuncti
WESTON, Fla. and ANN ARBOR, Mich.
Initiation of Clinical Study at Allegheny Health Network Seeks to Provide Treatment Options to Pancreatic Cancer Patients WESTON, Fla. and PITTSBURGH , Sept.
3 Tumbling Stocks to Take a Chance On Now
05:22am, Friday, 22'nd Sep 2023
Some investors believe that the market is always correct and that stock prices always accurately reflect reality. As a result, they will rarely if ever buy stocks that are tumbling and that are out of
Initiation of Clinical Study at Lenox Hill Hospital Seeks to Provide New Option for Treatment of Newly Diagnosed Unmethylated Glioblastoma WESTON, Fla. and NEW YORK , Sept.
